Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) immune checkpoint blockade with chemo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Kamath, Suneel D., Kalyan, Aparna, Kircher, Sheetal, Nimeiri, Halla, Fought, Angela J., Benson, Al, Mulcahy, Mary
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7216436/
https://ncbi.nlm.nih.gov/pubmed/31740568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0473
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados